Chinese biotech startup Excalipoint banks $69M for next-gen T cell engagers
admin Shanghai-based Excalipoint Therapeutics has announced the successful closure of a substantial financing round totaling $68.7...
drug development
Pfizer’s Atirmociclib Shows Promising Advances in Breast Cancer Treatment, Signaling a Strategic Shift in Oncology Pipeline
A new drug from Pfizer, atirmociclib, is emerging as a critical component of the pharmaceutical...
Bicycle Therapeutics Pivots from Bladder Cancer Challenger, Zelenectide, Amidst Intense Competition
Bicycle Therapeutics, a clinical-stage biopharmaceutical company leveraging its proprietary "Bicycle" technology to develop a novel...
R1 Therapeutics Launches with $77.5 Million, Unveiling Novel Oral Treatment for Chronic Kidney Disease Complication
Redwood City, California – March 17, 2026 – In a significant move set to potentially...
Structure Therapeutics’ Aleniglipron Shows “Injectable-Like Efficacy” in Promising Phase 2 Obesity Trial, Intensifying Oral GLP-1 Race
Structure Therapeutics, a rapidly emerging biotech firm, has announced compelling Phase 2 trial results for...
CytomX surges on positive data for ‘masked’ ADC in colorectal cancer
CytomX Therapeutics, a biopharmaceutical company focused on developing novel cancer therapies, announced on March 16,...
FDA Revolutionizes Product Safety Monitoring with Unified Surveillance Dashboard, Consolidating Disparate Systems for Enhanced Utility and Efficiency
The U.S. Food and Drug Administration (FDA) has announced a significant overhaul of its product...
Eli Lilly Urges FDA to Recall Compounded Zepbound, Citing "Dangerous" Impurities and "Unknown Risks" in Unauthorized Formulations
Eli Lilly has intensified its campaign against compounded versions of its blockbuster obesity drug Zepbound...
FDA Streamlines Biosimilar Approval Pathway to Boost Competition and Lower Drug Costs
The U.S. Food and Drug Administration (FDA) has announced significant draft guidance aimed at accelerating...
Biopharma Sector Navigates Layoffs, Regulatory Hurdles, and Clinical Breakthroughs as Companies Adapt to Evolving Market Dynamics
The biopharmaceutical landscape is currently characterized by a complex interplay of strategic restructurings, significant workforce...
